Compounds > 1-phenyl-2-decanoylamino-3-morpholino-1-propanol

1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Diabetes Mellitus, Type 2

1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Diabetes Mellitus, Type 2 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bandaru, VVR; Bedja, D; Campbell, SA; Chatterjee, S; Iocco, D; Kim, G; Ma, S; Rangecroft, AB; Zheng, L1

Other Studies

1 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Diabetes Mellitus, Type 2

ArticleYear
Management of metabolic syndrome and reduction in body weight in type II diabetic mice by inhibiting glycosphingolipid synthesis.
    Biochemical and biophysical research communications, 2020, 04-30, Volume: 525, Issue:2

    Topics: Animals; Anti-Obesity Agents; Body Weight; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycosphingolipids; Lipogenesis; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Morpholines

2020